請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83372
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊偉勛(Wei-Shiung Yang) | |
dc.contributor.author | Tzu-Yu Ko | en |
dc.contributor.author | 柯姿羽 | zh_TW |
dc.date.accessioned | 2023-03-19T21:05:56Z | - |
dc.date.copyright | 2022-10-13 | |
dc.date.issued | 2022 | |
dc.date.submitted | 2022-09-21 | |
dc.identifier.citation | 1. Chojdak-?ukasiewicz, J., et al., Cerebral small vessel disease: A review. Adv Clin Exp Med, 2021. 30(3): p. 349-356. 2. Cannistraro, R.J., et al., CNS small vessel disease: A clinical review. Neurology, 2019. 92(24): p. 1146-1156. 3. Litak, J., et al., Cerebral Small Vessel Disease. Int J Mol Sci, 2020. 21(24). 4. Choi, J.C., Genetics of cerebral small vessel disease. J Stroke, 2015. 17(1): p. 7-16. 5. Wang, T., M. Baron, and D. Trump, An overview of Notch3 function in vascular smooth muscle cells. Progress in biophysics and molecular biology, 2008. 96(1-3): p. 499-509. 6. Schoemaker, D. and J.F. Arboleda-Velasquez, Notch3 Signaling and Aggregation as Targets for the Treatment of CADASIL and Other NOTCH3-Associated Small-Vessel Diseases. Am J Pathol, 2021. 191(11): p. 1856-1870. 7. Rutten, J.W., et al., Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL. Ann Clin Transl Neurol, 2016. 3(11): p. 844-853. 8. Mui?o, E., et al., Systematic Review of Cysteine-Sparing NOTCH3 Missense Mutations in Patients with Clinical Suspicion of CADASIL. Int J Mol Sci, 2017. 18(9). 9. Ruchoux, M.M. and C.A. Maurage, CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol, 1997. 56(9): p. 947-64. 10. Baudrimont, M., et al., Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke, 1993. 24(1): p. 122-5. 11. Joutel, A., et al., The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest, 2000. 105(5): p. 597-605. 12. Yamamoto, Y., et al., Brain microvascular accumulation and distribution of the NOTCH3 ectodomain and granular osmiophilic material in CADASIL. J Neuropathol Exp Neurol, 2013. 72(5): p. 416-31. 13. Arboleda-Velasquez, J.F., et al., Notch signaling functions in retinal pericyte survival. Invest Ophthalmol Vis Sci, 2014. 55(8): p. 5191-9. 14. Baron-Menguy, C., et al., Increased Notch3 Activity Mediates Pathological Changes in Structure of Cerebral Arteries. Hypertension, 2017. 69(1): p. 60-70. 15. Fouillade, C., et al., Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain. Hum Mutat, 2008. 29(3): p. 452. 16. Nozaki, H., M. Nishizawa, and O. Onodera, Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke, 2014. 45(11): p. 3447-53. 17. M?ller, K., et al., New Insight Into the Pathogenesis of Cerebral Small-Vessel Diseases. Stroke, 2017. 48(2): p. 520-527. 18. Fukutake, T., Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis, 2011. 20(2): p. 85-93. 19. Martinvalet, D., P. Zhu, and J. Lieberman, Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity, 2005. 22(3): p. 355-70. 20. Cullen, S.P. and S.J. Martin, Mechanisms of granule-dependent killing. Cell Death Differ, 2008. 15(2): p. 251-62. 21. Crow, Y.J., et al., Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Gouti?res syndrome at the AGS1 locus. Nat Genet, 2006. 38(8): p. 917-20. 22. Haffner, C., R. Malik, and M. Dichgans, Genetic factors in cerebral small vessel disease and their impact on stroke and dementia. J Cereb Blood Flow Metab, 2016. 36(1): p. 158-71. 23. Tang, S.C., et al., Prevalence and clinical characteristics of stroke patients with p.R544C NOTCH3 mutation in Taiwan. Ann Clin Transl Neurol, 2019. 6(1): p. 121-128. 24. Lee, Y.C., et al., Characterization of Heterozygous HTRA1 Mutations in Taiwanese Patients With Cerebral Small Vessel Disease. Stroke, 2018. 49(7): p. 1593-1601. 25. Dorfman, R., The detection of defective members of large populations. The Annals of mathematical statistics, 1943. 14(4): p. 436-440. 26. Berger, T., J.W. Mandell, and P. Subrahmanya, Maximally efficient two-stage screening. Biometrics, 2000. 56(3): p. 833-40. 27. Furstenau, T.N., et al., Sample pooling methods for efficient pathogen screening: Practical implications. PLoS One, 2020. 15(11): p. e0236849. 28. Richards, S., et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015. 17(5): p. 405-24. 29. Greenberg, S.M., et al., Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol, 2009. 8(2): p. 165-74. 30. Bougea, A., et al., The first Greek case of heterozygous cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy: An atypical clinico-radiological presentation. Neuroradiol J, 2017. 30(6): p. 583-585. 31. Liu, J.Y., et al., HTRA1-related autosomal dominant cerebral small vessel disease. Chin Med J (Engl), 2020. 134(2): p. 178-184. 32. Hara, K., et al., Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med, 2009. 360(17): p. 1729-39. 33. Ohta, K., et al., Cerebral Small Vessel Disease Related to a Heterozygous Nonsense Mutation in HTRA1. Intern Med, 2020. 59(10): p. 1309-1313. 34. Liu, X., et al., The genetic spectrum and the evaluation of CADASIL screening scale in Chinese patients with NOTCH3 mutations. J Neurol Sci, 2015. 354(1-2): p. 63-9. 35. Onder, H., et al., R141C Mutation of NOTCH3 Gene in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. J Neurosci Rural Pract, 2017. 8(2): p. 301-303. 36. Ishibashi, K., et al., [Japanese CADASIL case with limited dementia who had the Notch 3 R141C mutation]. No To Shinkei, 2005. 57(5): p. 415-8. 37. Yadav, S., et al., The first Indian-origin family with genetically proven cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J Stroke Cerebrovasc Dis, 2013. 22(1): p. 28-31. 38. Lee, Y.C., et al., Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: two novel mutations in the NOTCH3 gene in Chinese. J Neurol Sci, 2006. 246(1-2): p. 111-5. 39. Zuluaga-Casta?o, Y., et al., Cognitive performance in asymptomatic carriers of mutations R1031C and R141C in CADASIL. Int J Psychol Res (Medellin), 2018. 11(2): p. 46-55. 40. Kano, Y., et al., Heterozygous Cysteine-sparing NOTCH3 Variant p.Val237Met in a Japanese Patient with Suspected Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy. Intern Med, 2021. 60(15): p. 2479-2482. 41. Guo, L., et al., The role of NOTCH3 variants in Alzheimer's disease and subcortical vascular dementia in the Chinese population. CNS Neurosci Ther, 2021. 27(8): p. 930-940. 42. Soong, B.W., et al., A homozygous NOTCH3 mutation p.R544C and a heterozygous TREX1 variant p.C99MfsX3 in a family with hereditary small vessel disease of the brain. J Chin Med Assoc, 2013. 76(6): p. 319-24. 43. Ji, T., et al., [Clinical and genetic analysis of a family with Aicardi-Gouti?res syndrome and literature review]. Zhonghua Er Ke Za Zhi, 2014. 52(11): p. 822-7. 44. Castello, J.P., et al., Cerebral Small Vessel Disease and Depression Among Intracerebral Hemorrhage Survivors. Stroke, 2022. 53(2): p. 523-531. 45. Hankey, G.J., Stroke. Lancet, 2017. 389(10069): p. 641-654. 46. Lee, Y.C., et al., NOTCH3 cysteine-altering variant is an important risk factor for stroke in the Taiwanese population. Neurology, 2020. 94(1): p. e87-e96. 47. Liao, Y.C., et al., Characterization of CADASIL among the Han Chinese in Taiwan: Distinct Genotypic and Phenotypic Profiles. PLoS One, 2015. 10(8): p. e0136501. 48. Kilarski, L.L., et al., Prevalence of CADASIL and Fabry Disease in a Cohort of MRI Defined Younger Onset Lacunar Stroke. PLoS One, 2015. 10(8): p. e0136352. 49. Razvi, S.S., et al., The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry, 2005. 76(5): p. 739-41. 50. Joutel, A., et al., Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature, 1996. 383(6602): p. 707-10. 51. Lee, Y.C., et al., Population-specific spectrum of NOTCH3 mutations, MRI features and founder effect of CADASIL in Chinese. J Neurol, 2009. 256(2): p. 249-55. 52. Chen, S., et al., Clinical features and mutation spectrum in Chinese patients with CADASIL: A multicenter retrospective study. CNS Neurosci Ther, 2017. 23(9): p. 707-716. 53. Giau, V.V., et al., Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome. Int J Mol Sci, 2019. 20(17). 54. Nozaki, H., et al., Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL. Neurology, 2016. 86(21): p. 1964-74. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83372 | - |
dc.description.abstract | 腦小血管疾病(CSVD)是最常見的慢性進行性血管疾病。此疾病導致約20-30%的中風,除了腦中風,腦小血管疾病也常以血管性失智症或血管性巴金森症等類神經退化性疾病為主要臨床表現。近年來,由於腦部影像檢查的進步及廣泛應用,腦小血管疾病在相關的臨床神經疾病扮演的角色愈發明確。 造成腦小血管疾病的病因有許多,常見的包括動脈硬化、類澱粉血管病變、發炎以及免疫有關的小血管病變。隨著基因診斷技術的快速發展,已鑑定出幾種由單基因變異引起的腦小血管疾病,如:自體顯性腦動脈血管病變合併皮質下腦梗塞及腦白質病變(CADASIL)、體隱性腦動脈血管病變合併皮質下腦梗塞及腦白質病變(CARASIL)、視網膜血管病變伴腦白質病變(RVCL)、COL4A1症候群、法布瑞氏症等,這五個疾病分別由不同基因變異所致病。 研究以次世代定序的技術分析臨床上懷疑為單基因變異引起腦小血管疾病的患者以及有腦出血症狀的患者,期望可以幫助這些患者找到致病原因,並了解本土基因變異分布的情形。本研究招募了133位懷疑為單基因變異引起腦小血管疾病的患者,以及432位有腦出血症狀的患者。實驗室根據文獻自行建立了CSVD panel,包含5個較常見與腦小血管疾病有關的基因:COL4A1, GLA, HTRA1, NOTCH3, TREX1。在133位懷疑為單基因變異引起腦小血管疾病的患者中我們找到了8個致病變異位點,檢出率約8%,以及11個意義尚未明確的變異位點。儘管目前對於CSVD 的病理和生理機制仍然不是很清楚。我們的研究探討了散發性的CSVD個案與CSVD有關之基因分布的情形,這將有助於幫助這類患者的診斷和治療。 相較於桑格定序,次世代定序是一個能大量平行定序,同時讀取上百萬條DNA序列的技術,可以在短時間內產出大量的數據,因此可以節省時間和花費。利用這項技術可以幫助患者找到造成腦小血管疾病的原因,此外,對台灣患者基因組成的了解擴大了我們對這種疾病的認識。 | zh_TW |
dc.description.abstract | Cerebral Small Vessel Disease (CSVD) is a major cause of cerebrovascular diseases. It contributes to about 20-30% of strokes. Besides stroke, patients with CSVD often present as symptoms of vascular dementia or parkinsonism, mimicking primary neurodegenerative disorders. In recent years, the crucial role of CSVD in neurological disorders becomes clinically apparent with the significant progress and empirical application of advanced neuroimaging techniques. Causes of CSVD are various. Common causes of CSVD include arteriosclerosis, cerebral amyloid angiopathy (CAA), inflammation and immune-mediated small vessel diseases. Along with the rapid progress of genetic diagnostic techniques, several types of monogenic hereditary cerebral SVD have been identified: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), Retinal vasculopathy with cerebral leukodystrophy and Fabry disease. This project used next generation sequencing technology (NGS) to screen variants in patients with CSVD or Intracerebral hemorrhage (ICH) , expecting to find out causes, and understand the distribution of gene variants in local patients situation. We recruited 133 patients with CSVD and 432 patients with ICH. We used the self-designed NGS CSVD panel including 5 genes: COL4A1, GLA, HTRA1, NOTCH3, TREX1 to screen the DNA of the recruited patients. In this study, we sequenced 133 patients with CSVD and yielded approximately 8% diagnosis rate with identifying 8 different disease-causing variants and several variants of unknown significant (VUS). Although the pathophysiologic mechanisms of CSVD are not yet clear. Our study explored the status of multiple known monogenic CSVD genes in the sporadic population. This will help doctors identify what is causing patients symptoms and improves the quality of clinical decisions. Comparing with Sanger sequencing methods, next-generation sequencing (NGS) is a massively parallel sequencing technology. This process generates high throughputs with high resolution within several days. Using this technology can help patients find the cause of cerebral small vessel disease (CSVD). In addition, understanding of genetic composition of Taiwan patients expands our understanding of cerebral small vessel disease (CSVD). | en |
dc.description.provenance | Made available in DSpace on 2023-03-19T21:05:56Z (GMT). No. of bitstreams: 1 U0001-1109202220301100.pdf: 2307361 bytes, checksum: 31095ccddd214f013a9eec7ce293a3ca (MD5) Previous issue date: 2022 | en |
dc.description.tableofcontents | 誌謝 ....................................................... i 中文摘要 ................................................... ii 英文摘要 .................................................. iii 目錄 ........................................................ v 第一章 研究背景與動機 ........................................ 1 1.1 腦小血管疾病.............................................. 1 1.2 腦小血管疾病之基因概論 .................................... 2 1.3 研究動機 ................................................. 9 第二章 研究方法 .............................................. 10 2.1 研究對象 ................................................ 10 2.1.1 納入條件(1) .......................................... 10 2.1.2 排除條件(1) .......................................... 10 2.1.3 納入條件(2) .......................................... 10 2.2 實驗方法 ................................................. 11 2.2.1 Genomic DNA的萃取 ...................................... 11 2.2.2 偵測DNA品質............................................. 11 2.2.3 檢體匯集(Pooling) ..................................... 12 2.2.4 次世代定序實驗製備 ...................................... 12 2.2.5 次世代定序分析 .......................................... 13 2.2.6 變異位點致病性之判讀準則 ................................. 14 2.2.7 聚合?鏈鎖反應(PCR)及桑格定序法(Sanger Sequencing) .... 14 第三章 結果 ................................................... 15 3.1 次世代定序分析結果 ......................................... 15 3.1.1 腦小血管疾病患者分析結果 .................................. 15 3.1.2 腦出血患者分析結果 ....................................... 22 3.1.3 案例 .................................................... 24 第四章 討論 .................................................... 26 4.1 台灣人特有腦中風突變基因NOTCH3 c.1630C>T, p.R544C ........... 26 4.2 HTRA1基因之遺傳模式 ........................................ 27 4.3 CSVD平台建立對於臨床之益處................................... 27 4.4 檢體匯集之分析 ............................................. 27 4.5 未來展望 ................................................... 28 參考文獻 ....................................................... 29 附錄 ........................................................... 33 | |
dc.language.iso | zh-TW | |
dc.title | 台灣腦小血管病變之基因研究 | zh_TW |
dc.title | Genetic Study of Cerebral Small Vessel Disease (CSVD) in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 110-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳沛隆(Pei-Lung Chen) | |
dc.contributor.oralexamcommittee | 湯頌君(Sung-Chun Tang) | |
dc.subject.keyword | 腦小血管疾病,腦出血,失智,基因檢測,次世代定序,單基因, | zh_TW |
dc.subject.keyword | Cerebral Small Vessel Disease,Intracerebral hemorrhage,genetic testing,dementias,single gene,next-generation sequencing (NGS), | en |
dc.relation.page | 34 | |
dc.identifier.doi | 10.6342/NTU202203289 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2022-09-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1109202220301100.pdf 目前未授權公開取用 | 2.25 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。